Sale!

CA CYFRA 21-1 Lung Cancer Marker Test

640 د.إ

-10%

The CA CYFRA 21-1 Lung Cancer Marker Test is a specialized diagnostic tool designed to aid in the detection and monitoring of non-small cell lung cancer (NSCLC). This test measures the levels of CYFRA 21-1, a tumor marker that is often elevated in individuals with lung cancer, especially those with NSCLC. By quantifying the amount of CYFRA 21-1 present in the blood, healthcare providers can assess the presence and progression of the disease, as well as monitor the effectiveness of treatment.

Offered at DNA Labs UAE, a leading facility in medical diagnostics, the CA CYFRA 21-1 Lung Cancer Marker Test is available for 640 AED. This cost-effective option provides patients and doctors with critical information that can guide treatment decisions and improve patient outcomes. DNA Labs UAE is known for its commitment to accuracy, reliability, and patient care, ensuring that individuals undergoing the CA CYFRA 21-1 test receive comprehensive support throughout their diagnostic journey.

Home  Sample collection service available

  • 100% accuaret DNA Results
  • Ranked as Most trusted Genetic DNA Lab
Guaranteed Safe Checkout

CA CYFRA 21-1 LUNG CANCER MARKER Test

Test Name: CA CYFRA 21-1 LUNG CANCER MARKER Test

Components: CYFRA 21-1

Price: 640.0 AED

Sample Condition: 2 mL (0.5 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide brief clinical history.

Report Delivery: 1 week

Method: Electrochemiluminescence

Test type: Cancer

Doctor: Oncologist, Chest Physician

Test Department: DNA Labs UAE

Pre Test Information

Provide brief clinical history.

Test Details

CYFRA 21-1 is a tumor marker used for the detection and monitoring of lung cancer. It measures the levels of cytokeratin 19 fragments in the blood, which are released by lung cancer cells.

The CYFRA 21-1 test is commonly used in combination with other diagnostic tests, such as imaging scans and biopsies, to help diagnose lung cancer and determine its stage. It can also be used to monitor the effectiveness of treatment and detect any recurrence of the cancer.

A blood sample is taken from the patient and sent to a laboratory for analysis. The results are usually reported as a numerical value, with higher levels indicating a higher likelihood of lung cancer.

It’s important to note that while the CYFRA 21-1 test is a useful tool in the diagnosis and management of lung cancer, it is not definitive and should be used in conjunction with other clinical and diagnostic information.

If you have any concerns about lung cancer or are experiencing symptoms, it is recommended to consult with a healthcare professional who can provide appropriate guidance and testing options.

Test Name CA CYFRA 21-1 LUNG CANCER MARKER Test
Components
Price 640.0 AED
Sample Condition 2 mL (0.5 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide brief clinical history.
Report Delivery 1 week
Method Electrochemiluminescence
Test type Cancer
Doctor Oncologist, Chest Physician
Test Department:
Pre Test Information Provide brief clinical history.
Test Details

CYFRA 21-1 is a tumor marker used for the detection and monitoring of lung cancer. It measures the levels of cytokeratin 19 fragments in the blood, which are released by lung cancer cells.

The CYFRA 21-1 test is commonly used in combination with other diagnostic tests, such as imaging scans and biopsies, to help diagnose lung cancer and determine its stage. It can also be used to monitor the effectiveness of treatment and detect any recurrence of the cancer.

A blood sample is taken from the patient and sent to a laboratory for analysis. The results are usually reported as a numerical value, with higher levels indicating a higher likelihood of lung cancer.

It’s important to note that while the CYFRA 21-1 test is a useful tool in the diagnosis and management of lung cancer, it is not definitive and should be used in conjunction with other clinical and diagnostic information.

If you have any concerns about lung cancer or are experiencing symptoms, it is recommended to consult with a healthcare professional who can provide appropriate guidance and testing options.